- Home
- SRAD vs APLS Comparison
SRAD vs APLS Comparison
Compare SRAD & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRAD | APLS |
|---|---|---|
| Founded | 2001 | 2009 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.2B |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SRAD | APLS |
|---|---|---|
| Price | $12.49 | $41.04 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 21 |
| Target Price | $24.31 | ★ $33.59 |
| AVG Volume (30 Days) | 5.5M | ★ 6.7M |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 112.50 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $1,003,782,000.00 |
| Revenue This Year | $24.03 | N/A |
| Revenue Next Year | $14.81 | $18.19 |
| P/E Ratio | ★ $49.48 | $273.60 |
| Revenue Growth | N/A | ★ 28.46 |
| 52 Week Low | $11.66 | $16.61 |
| 52 Week High | $32.22 | $41.14 |
Technical Indicators
Market Signals| Indicator | SRAD | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 36.06 | 84.57 |
| Support Level | $11.66 | $19.29 |
| Resistance Level | $14.44 | $41.14 |
| Average True Range (ATR) | 0.82 | 0.06 |
| MACD | 0.06 | -0.65 |
| Stochastic Oscillator | 29.68 | 58.33 |
Price Performance
Historical ComparisonAbout SRAD Sportradar Group AG
Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing. Geographically, it operates in North America, Africa, AsiaPac & Middle East, Europe, and LATAM & Caribbean.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).